Refine your search:     
Report No.
 - 
Search Results: Records 1-18 displayed on this page of 18
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

Journal Articles

Production of iodine radionuclides using $$^{7}$$Li ion beams

Nishinaka, Ichiro*; Yokoyama, Akihiko*; Washiyama, Koshin*; Makii, Hiroyuki; Hashimoto, Kazuyuki*

Journal of Radioanalytical and Nuclear Chemistry, 314(3), p.1947 - 1965, 2017/12

 Times Cited Count:2 Percentile:28.88(Chemistry, Analytical)

Production cross sections of iodine, tellurium and antimony radionuclides in the 24-59 MeV $$^{7}$$Li + $$^{nat}$$Sn reaction have been measured by the conventional stacked foil technique with $$gamma$$-ray spectrometry. Excitation functions of the production cross sections were compared with a statistical model calculation. The contributions of complete and incomplete fusion in the production of observed radionuclides are discussed from the view points of production routes in the nuclide chart and decays for iodine, tellurium and antimony nuclides. The integral yields of $$^{123,124,125,126}$$I were deduced from the calculated excitation functions in the $$^{7}$$Li induced reactions on Sn isotopes in view of the production of medically important $$^{123,124}$$I. The results are discussed by comparing with literature values in the other reactions.

Journal Articles

Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for $$alpha$$ radionuclide therapy

Ogawa, Kazuma*; Mizuno, Yoshiaki*; Washiyama, Koshin*; Shiba, Kazuhiro*; Takahashi, Naruto*; Kozaka, Takashi*; Watanabe, Shigeki; Shinohara, Atsushi*; Odani, Akira*

Nuclear Medicine and Biology, 42(11), p.875 - 879, 2015/11

 Times Cited Count:18 Percentile:69.85(Radiology, Nuclear Medicine & Medical Imaging)

Journal Articles

Production and separation of astatine isotopes in the $$^7$$Li + $$^{nat}$$Pb reaction

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Maeda, Eita*; Watanabe, Shigeki; Hashimoto, Kazuyuki; Ishioka, Noriko; Makii, Hiroyuki; Toyoshima, Atsushi; Yamada, Norihiro*; et al.

Journal of Radioanalytical and Nuclear Chemistry, 304(3), p.1077 - 1083, 2015/06

 Times Cited Count:9 Percentile:69.75(Chemistry, Analytical)

Production cross sections of astatine isotopes $$^{207-211}$$At in the 29-57 MeV $$^7$$Li induced reaction with $$^{nat}$$Pb target have been measured by $$alpha$$- and $$gamma$$-ray spectrometry. Excitation functions of production cross sections have been compared with a statistical model calculation to study the reaction mechanism of $$^7$$Li + $$^{nat}$$Pb. Considerably small experimental cross sections of $$^{210}$$At and $$^{209}$$At compared with the calculation were clearly observed at incident energies higher than 44 MeV, indicating that the effects of breakup reaction play a role. A chemical separation of astatine from an irradiated lead target has been studied with a dry-distillation method. A complementary way to produce astatine isotopes has been developed.

Journal Articles

Extraction of astatine isotopes for development of radiopharmaceuticals using a $$^{211}$$Rn-$$^{211}$$At generator

Maeda, Eita*; Yokoyama, Akihiko*; Taniguchi, Takumi*; Washiyama, Koshin*; Nishinaka, Ichiro

Journal of Radioanalytical and Nuclear Chemistry, 303(2), p.1465 - 1468, 2015/02

 Times Cited Count:8 Percentile:60.95(Chemistry, Analytical)

The $$^{211}$$At isotope has gathered attention as a promising $$alpha$$-emitter for radionuclide therapy. We report the dependence of the distribution ratio of astatine on the concentration of HCl, and on the polarity of the organic solvent. The results will be useful for development of the $$^{211}$$Rn-$$^{211}$$At generator.

Journal Articles

Assessment of olfactory nerve by SPECT-MRI image with nasal thallium-201 administration in patients with olfactory impairments in comparison to healthy volunteers

Shiga, Hideaki*; Taki, Junichi*; Washiyama, Koshin*; Yamamoto, Jumpei*; Kinase, Sakae; Okuda, Koichi*; Kinuya, Seigo*; Watanabe, Naoto*; Tonami, Hisao*; Koshida, Kichiro*; et al.

PLOS ONE (Internet), 8(2), p.e57671_1 - e57671_8, 2013/02

 Times Cited Count:14 Percentile:67.39(Multidisciplinary Sciences)

Journal Articles

Internal dosimetry for nasal thallium-201 administration

Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*

KEK Proceedings 2012-7, p.35 - 40, 2012/10

no abstracts in English

Journal Articles

Photofission of $$^{209}$$Bi at intermediate energies

Haba, Hiromitsu; Kasaoka, Makoto*; Igarashi, Manabu*; Washiyama, Koshin*; Matsumura, Hiroshi*; Oura, Yasuji*; Shibata, Seiichi*; Sakamoto, Ko*; Furukawa, Michiaki*; Fujiwara, Ichiro*

Radiochimica Acta, 90(7), p.371 - 382, 2002/08

 Times Cited Count:2 Percentile:17.59(Chemistry, Inorganic & Nuclear)

The reaction yields of 63 radionuclides with the mass number A = 56-135 produced in the photofission of $$^{209}$$Bi by bremsstrahlung of end-point energies (E$$_{0}$$) from 450 to 1100 MeV have been measured using a catcher foil technique. The charge distribution was well reproduced by a Gaussian function with the most probable charge (Z$$_{p}$$) expressed by Z$$_{p}$$ = RA + S, and with the A-independent FWHME$$_{CD}$$. The charge distribution parameters R, S and FWHM$$_{CD}$$ were independent of E$$_{0}$$ above 600 MeV. The weighted mean values at E$$_{0}$$ $$geq$$ 600 MeV were R = 0.421 $$pm$$ 0.001, S = 0.6 $$pm$$ 0.1 and FWHM$$_{CD}$$ = 2.1 $$pm$$ 0.1 charge unit (c.u.). Based on the charge distribution parameters, the symmetric mass yield distributions with the most probable mass A$$_{p}$$ of 96 $$pm$$ 1 mass unit (m.u.) and the width FWHM$$_{MD}$$ of 33 $$pm$$ 1 m.u. were also obtained. The characteristics of the charge and mass yield distributions are discussed by referring to those for $$^{197}$$Au based on the results of calculations using PICA3/GEM.

Oral presentation

Nuclear and radiochemical study of production and utilization of radioactive astatine isotopes using lithium ion beams at the tandem accelerator of JAEA-Tokai

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Yamada, Norihiro*; Ishiguro, Rika*; Makii, Hiroyuki; Hashimoto, Kazuyuki

no journal, , 

An $$alpha$$ radioactive nuclide $$^{211}$$At is a prospective candidate for utilization in targeted alpha radiotherapy. We have started nuclear and radiochemical study of production and utilization of radioactive astatine isotopes using lithium ion beams at the tandem accelerator of JAEA-Tokai. We determined the excitation functions of astatine isotopes in the reaction of 29-48 MeV $$^7$$Li+$$^{nat}$$Pb and studied a chemical behavior of carrier-free radioactive astatine isotopes with a dry-chemistry method. Details will be shown in the presentation.

Oral presentation

Production of astatine radioisotopes in the $$^7$$Li+$$^{nat}$$Pb reaction and simple chemical separation of astatine

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Ri, Keiko*; Yamada, Norihiro*; Ishiguro, Rika*; Maeda, Eita*; Makii, Hiroyuki; Hashimoto, Kazuyuki; et al.

no journal, , 

We have started to study production and utilization of an $$alpha$$ radioactive nuclide $$^{211}$$At which is a prospective candidate for targeted alpha radiotherapy. We determined production cross sections of astatine radioisotopes in the reaction of 29-48 MeV $$^7$$Li+$$^{nat}$$Pb by $$alpha$$-ray and $$gamma$$-ray spectrometry at the tandem accelerator of JAEA-Tokai. Besides, we developed a simple dry-chemical method for separation of astatine.

Oral presentation

Nuclear and radiochemical study of production and utilization of radioactive astatine isotopes in the Li + $$^{nat}$$Pb reaction

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Yamada, Norihiro*; Makii, Hiroyuki; Watanabe, Shigeki; Ishioka, Noriko; Hashimoto, Kazuyuki

no journal, , 

Oral presentation

Nuclear and radiochemical study of production and utilization of radioactive astatine isotopes in the Li+$$^{nat}$$Pb reaction; Aim at the new cancer medical treatment by $$alpha$$-emitting radioisotopes

Nishinaka, Ichiro; Makii, Hiroyuki; Toyoshima, Atsushi; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Yamada, Norihiro*; Taniguchi, Takumi*; Watanabe, Shigeki; et al.

no journal, , 

no abstracts in English

Oral presentation

Production and utilization of radioactive astatine isotopes in the $$^7$$Li + $$^{nat}$$Pb reaction

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Yamada, Norihiro*; Makii, Hiroyuki; Toyoshima, Atsushi; Watanabe, Shigeki; Ishioka, Noriko; et al.

no journal, , 

Production cross sections of astatine in 29-57 MeV $$^7$$Li + $$^{rm nat}$$Pb have been measured by $$alpha$$- and $$gamma$$-ray spectrometry. Excitation functions of production cross sections have been compared with a statistical model calculation to study the reaction mechanism of the $$^7$$Li + $$^{rm nat}$$Pb reaction. It indicates that the breakup of $$^7$$Li plays a rule in the $$^7$$Li + $$^{rm nat}$$Pb reaction. Besides, we have developed a dry-distillation method which separates carrier-free astatine from an irradiated lead target.

Oral presentation

Production and separation of radioactive astatine isotopes in the $$^7$$Li+$$^{nat}$$Pb reaction

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Yamada, Norihiro*; Makii, Hiroyuki; Toyoshima, Atsushi; Watanabe, Shigeki; Ishioka, Noriko; et al.

no journal, , 

To promote utilization of a radioactive nuclide $$^{211}$$At which draws increasing attention as a promissing $$alpha$$-emitter for targeted alpha therapy, we have measured production cross sections of astatine isotopes in the 29-57 MeV$$^7$$Li+$$^{nat}$$Pb reaction using the tandem accelerator of JAEA-Tokai, providing nuclear data for production. For pharmaceutical study and so on, beside, we have developed a new separation procedure based on a dry-distillation method which separates carrier free astatine isotopes from lead targets with high radiochemical and chemical purity and high yields.

Oral presentation

Evaluation of S values for organs from nasal administration of Tl-201

Kinase, Sakae; Washiyama, Koshin*; Shiga, Hideaki*; Taki, Junichi*; Nakanishi, Yusuke*; Koshida, Kichiro*; Miwa, Takaki*; Kinuya, Seigo*; Amano, Ryohei*

no journal, , 

no abstracts in English

Oral presentation

Production and utilization of astatine radioisotopes using $$^{7}$$Li ion beams

Nishinaka, Ichiro; Yokoyama, Akihiko*; Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Taniguchi, Takumi*; Murakami, Kento*; Watanabe, Shigeki; Suzuki, Hiroyuki; Ishioka, Noriko; et al.

no journal, , 

In general, an $$alpha$$-emitter $$^{211}$$At which is a prospective candidate for utilization in targeted alpha radiotherapy is produced through the $$^{209}$$Bi($$^{4}$$He, 2n)$$^{211}$$At reaction. In contrast, our project is focusing on the production in the $$^{209}$$Bi($$^{7}$$Li, 5n)$$^{211}$$Rn reaction. This enables us to supply $$^{211}$$At in a $$^{211}$$Rn/$$^{211}$$At generator system. The daughter $$^{211}$$At (7.2 h half-life) is extracted from the parent $$^{211}$$Rn (14h), expanding time-frame for transportation and use of $$^{211}$$At. To use astatine and iodine radioisotopes in our project, the excitation functions of $$^{209}$$Bi($$^{7}$$Li, xn)$$^{216-x}$$Rn, $$^{nat}$$Pb($$^{7}$$Li, xn)$$^{nat-x}$$At and $$^{nat}$$Sn($$^{7}$$Li, xn)$$^{nat-x}$$I reactions have been measured. In addition to that, separation techniques have been developed. We report not only on the production and separation of astatine and iodine radioisotopes in the reactions but also on the utilization of those radioisotopes.

Oral presentation

Development of $$^{211}$$Rn/$$^{211}$$At generator for targeted alpha therapy

Washiyama, Koshin*; Maeda, Eita*; Yokoyama, Akihiko*; Nishinaka, Ichiro; Taniguchi, Takumi*; Yamada, Norihiro*; Makii, Hiroyuki; Toyoshima, Atsushi; Amano, Ryohei*

no journal, , 

A $$^{211}$$Rn/$$^{211}$$At generator for targeted alpha therapy has been developed.

Oral presentation

Production of $$^{211}$$At for alpha radiotherapy via $$^{209}$$Bi($$^7$$Li,5n)$$^{211}$$Rn

Nishinaka, Ichiro; Washiyama, Koshin*; Yokoyama, Akihiko*; Maeda, Eita*; Hashimoto, Kazuyuki; Makii, Hiroyuki

no journal, , 

A $$^{211}$$Rn/$$^{211}$$At generator has been proposed to supply a radiotracer $$^{211}$$At with a half-life (T$$_{1/2}$$ = 7.2 h) for medical applications. To establish a technology of the $$^{211}$$Rn/$$^{211}$$At generator, $$^{211}$$Rn (T$$_{1/2}$$ = 14.7 h) has to be produced through the $$^{209}$$Bi($$^7$$Li, 5n)$$^{211}$$Rn reaction without melting bismuth metal targets due to heat produced by the irradiation of 60 MeV $$^7$$Li ion beams. In this work, we have studied the effects of a He gas cooling system of an irradiation chamber constructed for the production of $$^{211}$$Rn. Irradiations were carried out at the JAEA tandem accelerator using the irradiation chamber equipped with the He gas cooling system. The results show that the He gas effectively cools the targets and the cooling efficiency is nearly independent of the pressure ($$>$$ 1 kPa) and the flow rate ($$sim$$20 L/min) of the He gas.

Oral presentation

Production of alpha-emitting radioisotopes using the cyclotron facilities at Osaka University and JAEA Takasaki, and the Tandem accelerator at Tokai, JAEA

Washiyama, Koshin*; Amano, Ryohei*; Maeda, Eita*; Yokoyama, Akihiko*; Nishinaka, Ichiro; Takahashi, Naruto*; Shinohara, Atsushi*; Watanabe, Shigeki; Ishioka, Noriko

no journal, , 

In order to use of an alpha emitter for targeted alpha therapy, we have started the production and the utilization of $$^{211}$$At using 30 MeV $$^4$$He particle in the $$^{209}$$Bi($$^4$$He, 2n)$$^{211}$$At nuclear reaction at cyclotron facilities of Osaka University and JAEA Takasaki. In addition to that, we have been developing a $$^{211}$$Rn/$$^{211}$$At generator to expand the availability of $$^{211}$$At to wide range of populations far away from cyclotron facilities. The results of studies on the At-chemistry for clinical use and on the development of the $$^{211}$$Rn/$$^{211}$$At generator will be presented. And a review of current status of targeted alpha therapy in Japan will be also introduced.

18 (Records 1-18 displayed on this page)
  • 1